Your browser doesn't support javascript.
loading
Evolving growth hormone deficiency: proof of concept.
Chimatapu, Sri Nikhita; Sethuram, Swathi; Samuels, Julie G; Klomhaus, Alexandra; Mintz, Cassie; Savage, Martin O; Rapaport, Robert.
Afiliación
  • Chimatapu SN; Division of Pediatric Endocrinology, University of California, Los Angeles (UCLA) Mattel Children's Hospital, Los Angeles, CA, United States.
  • Sethuram S; Division of Pediatric Endocrinology, Massachusetts General Hospital, Boston, MA, United States.
  • Samuels JG; Division of Pediatric Endocrinology and Diabetes, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Klomhaus A; Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
  • Mintz C; Division of Medical Genetics & Genomics, Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Savage MO; William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, University of London, Queen Mary, United Kingdom.
  • Rapaport R; Division of Pediatric Endocrinology and Diabetes, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Front Endocrinol (Lausanne) ; 15: 1398171, 2024.
Article en En | MEDLINE | ID: mdl-38752175
ABSTRACT

Introduction:

We present the evolution of GHD in adolescent males with persistent growth failure, in whom the diagnosis was established after a second GH stimulation test (GST).

Methods:

We performed a retrospective chart review of children who presented for short stature (height less < 2SD for mean/mid-parental height) and/or growth failure (sustained growth velocity < 0 SD) to pediatric endocrinology at Mount Sinai Kravis Children's Hospital, New York and who had 2 GSTs. Data collected from electronic medical records were analyzed using SPSS v28.0.

Results:

Of 53 patients included, 42 were males. Average GH peak on initial GST was 15.48 ± 4.92 ng/ml, at 10.07 ± 2.65 years, mean height -1.68 ± 0.56SD(28% had <2SD), IGF-1 -1.00 ± 0.88SD. After 2.23 ± 1.22 years, at 12.04 ± 2.41years, height SDs decreased to -1.82 ± 0.63SD and IGF-1 was -1.08 ± 0.84SD. At repeat GST, average GH peak was 7.59 ± 2.12 ng/dL, with 36% ≤7 ng/dl and 32% in puberty. 12 males reached adult height of 0.08 ± 0.69 SD with a mean height gain of 1.83 ± 0.56SD(p<0.005), IGF-1 of -1.15 ± 0.81SD after 4.64 ± 1.4 years of GH.

Conclusion:

We offer evidence for Evolving Growth Hormone Deficiency (EGHD) through repeat GST in children with persistent growth slowdown, even with pubertal progression; emphasizing the need for careful longitudinal follow-up to make accurate diagnosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hormona de Crecimiento Humana / Trastornos del Crecimiento Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hormona de Crecimiento Humana / Trastornos del Crecimiento Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos